Cancer Research Institute (CRI) shared a post on LinkedIn:
“While melanoma and lung cancer have seen dramatic survival gains, many cancers remain resistant to current immunotherapies. The 5 year survival rate for pancreatic cancer remains at just 13%, and uterine corpus cancer mortality has risen for 26 consecutive years.
Discover what lies ahead for immunotherapy, and explore what can be done to continue to unlock its potential for all patients.”
Other articles from Cancer Research Institute.